Camrelizumab Combined With Pemetrexed and Carboplatin for the Study of EGFR-mutated Lung Squamous NSCLC Treatment
A single-arm, prospective, single-center, phase II, exploratory study investigating Camrelizumab combined with pemetrexed and carboplatin in the treatment of advanced non-squamous cell non-small-scale EGFR mutations (EGFR-TKI treatment failure ) Effectiveness of cell lung cancer patients
Lung Cancer Stage II
DRUG: Camrelizumab+ pemetrexed + platinum
Progression-free survival, From the date Into this study to tumor progression or death for any, 1 Year
Objective response rate, it is defined as the proportion of patients whose tumors shrink to a predetermined size and maintain a minimum time limit. It includes the cases of CR and PR., 2 Year|Overall survival, The time from the beginning of treatment to the death of the subject due to various reasons, calculated by the intended treatment population, 2 Year|Disease Control Rate, the rate of CR, PR plus SD, 2 Year|Duration of Response, Cr or PR to the first assessment of PD or death from any cause, 2 Year
In this study, eligible subject will be Subjects will have the opportunity to receive the treatment of Camrelizumab in combination with pemetrexed and carboplatin therapy .